Stockholm-based Epigenica AB has secured $2.2 million in funding to accelerate the commercialization of its high-throughput epigenetic screening platform, positioning the company to capitalize on the growing integration of epigenetics into multi-omics research and drug development.
The funding round was led by Voima Ventures, a Nordic early-stage investor specializing in science-based solutions, with participation from deep tech investor Navigare Ventures, social impact-focused Leksell Social Ventures, and existing shareholder Almi Invest.
EpiFinder Platform Addresses Multi-Omics Gap
Epigenica's proprietary EpiFinder platform enables simultaneous analysis of multiple epigenetic markers across large numbers of samples with exceptional resolution and efficiency. The technology is powered by the company's patented high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), providing scalable, cost-effective epigenomic profiling using various starting materials.
"The field of epigenetics, which studies how our lifestyle and environment impact the way our genes work, holds transformative potential in areas like oncology, longevity and drug development," said Stina Wallmark, Voima Ventures Investment Director. "Epigenica enables fast, scalable and affordable analysis of epigenetic biomarkers, helping researchers fully unlock the potential of multi-omics in the search for new diagnostics and therapies."
With advances in RNA, protein, and metabolite analysis driving the rise of multi-omics approaches, epigenetics is emerging as the next essential layer in this framework, adding unique insights into how biological processes are organized and regulated.
Product Portfolio Expansion and Market Entry
The funding will accelerate development and commercialization of Epigenica's flagship products, including the already available EpiFinder Genome and upcoming EpiFinder Global and EpiFinder cNUC kits. The investment will also support the build-out of the company's service offering and data infrastructure, as well as its expansion into the U.S. market.
"Since Epigenica's founding, we've refined our technology into a broad portfolio of products serving a diverse range of epigenetics applications," said Mohamad Takwa, CEO of Epigenica. "We anticipate a number of significant product launches in the coming year that will enable our customers to improve and expand their research."
Technology Applications Across Therapeutic Areas
Epigenica offers a broad product portfolio to support diverse applications in oncology, pharmaceutical development, and longevity research. The platform provides insights into how lifestyle and environmental factors influence gene activity, ultimately shaping disease outcomes and treatment strategies.
The company's technology is designed to help customers generate actionable insights to advance multi-omics and translational research, enable biomarker discovery, and accelerate next-generation sequencing applications to improve human health.
"This funding is a strong validation of our scientific and commercial progress," Takwa added, expressing confidence in the ongoing support from both new and existing shareholders.
